CAS: 23612-57-9; 2-Amino-3-Hydroxymethylpyridine

相似化合物

14667-47-1 5345-47-1 7521-41-7

上下游产品

CAS号5345-47-1 2-氨基烟酸 | CAS号86847-64-5 N-(3-甲酰基-2-吡啶基)... | CAS号13362-26-0 2-氨基烟酸乙酯 | CAS号111477-17-9 咪唑并[1,2-a]吡啶-8-基甲醇 | CAS号335031-01-1 2-氨基-5-溴-3-(羟甲基)吡啶 | CAS号335031-10-2 6-溴-2-氧代-2,3,4,... | CAS号443956-55-6 2-氨基-5-溴-3-(羟甲基... | CAS号129686-16-4 6-溴-3,4-二氢-1H-[... | CAS号709650-05-5 7-溴-4,5-二氢-1H-吡... | CAS号858431-27-3 2-AMINO-3-CHLOR...

2-氨基烟酸乙酯置于lithium Aluminium Tetrahydride体系中,用 四氢呋喃,乙醚 用作溶剂,化学反应 1.5H,反应生成2-氨基-3-羟甲基吡啶
参考文献:Nicotinamide Derivatives Useful As Pde4 Inhibitors
标题:Nicotinamide Derivatives Useful As Pde4 Inhibitors
摘要:这项发明涉及一般式(i)的烟酰胺衍生物:其中x,Y,N,Z,L和r具有本文中定义的含义,以及用于制备,制备中间体,含有和使用这种衍生物的过程.

专利信息

专利号:US-2003069417-A1
优先权日:1999-04-19
标题:Novel synthesis and crystallization of piperazine ring-containing compounds
发明人：SINGER CLAUDE; LIBERMAN ANITA; FINKELSTEIN NINA
摘要:The present invention is directed to methods for the preparation of piperazine ring-containing compounds, particularly mirtazapine. According to the present invention, the mirtazapine intermediate 1-(3-carboxypyridyl-2)-4-methyl-2-phenyl-piperazine is made by hydrolyzing 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine with a base where the base is present in a ratio of up to about 12 moles of the base per one mole of 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine. The mirtazapine intermediate 1-(3-carboxypyridyl-2)-4-methyl-2-phenyl-piperazine may be made of hydrolyzing 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine with potassium hydroxide at a temperature of at least about 130° C. The method of the present invention also includes reacting 2-amino-3-hydroxymethyl pyridine with N-methyl-1-phenyl-2,2′-iminodiethyl chloride to form 1-(3-hydroxymethylpyridyl-2)-4-methyl-2-phenyl piperazine, and adding sulfuric acid to the 1-(3-hydroxymethylpyridyl-2)-phenyl-4-methylpiperazine to form mirtazapine. The present invention a recrystallization of mirtazapine from crude mirtazapine. The present invention also relates to crystalline adducts of mirtazapine and water, preferably containing up to about 3.5% by weight water, pharmaceutical compositions containing the crystalline adducts, and methods of treating depression by administering such compositions.

专利号:WO-0062782-A1
优先权日:1999-04-19
标题 :Novel synthesis and crystallization of piperazine ring-containing compounds
发明人：SINGER CLAUDE; LIBERMAN ANITA; FINKELSTEIN NINA
权利人:TEVA PHARMA; TEVA PHARMA; SINGER CLAUDE; LIBERMAN ANITA; FINKELSTEIN NINA
摘要:The present invention is directed to methods for the preparation of piperazine ring-containing compounds, particularly mirtazapine. According to the present invention, the mirtazapine intermediate 1-(3-carboxypyridyl-2)-4-methyl-2-phenyl-piperazine is made by hydrolyzing 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine with a base where the base is present in a ratio of up to about 12 moles of the base per one mole of 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine. The mirtazapine intermediate 1-(3-carboxypyridly-2)-4-methyl-2-phenyl-piperazine may be made by hydrolyzing 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine with potassium hydroxide at a temperature of at least about 130 °C. The method of the present invention also includes reacting 2-amino-3-hydroxymethyl pyridine with N-methyl-1-phenyl-2, 2'-iminodiethyl chloride to form 1-(3-hydroxymethylpyridyl-2)-4-methyl-2-phenyl piperazine, and adding sulfuric acid to the 1-(3-hydroxymethylpyridyl-2)-phenyl-4-methylpiperazine to form mirtazapine. The present invention also relates to new processes for recrystallization of mirtazapine form crude mirtazapine.

专利号:CN-112876470-B
优先权日:2019-11-29
标 题 :A kind of method for the synthesis of non-metallic catalyzed quinazolinone compounds without additives

专利号:US-6576764-B2
优先权日:1999-04-19
标 题:Synthesis and crystallization of piperazine ring-containing compounds
发明人：SINGER CLAUDE; LIBERMAN ANITA; FINKELSTEIN NINA
权利人:TEVA PHARMA
摘要:The present invention is directed to methods for the preparation of piperazine ring-containing compounds, particularly mirtazapine. According to the present invention, the mirtazapine intermediate 1-(3-carboxypyridyl-2)-4-methyl-2-phenyl-piperazine is made by hydrolyzing 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine with a base where the base is present in a ratio of up to about 12 moles of the base per one mole of 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine. The mirtazapine intermediate 1-(3-carboxypyridyl-2)-4-methyl-2-phenyl-piperazine may be made by hydrolyzing 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine with potassium hydroxide at a temperature of at least about 130° C. The method of the present invention also includes reacting 2-amino-3-hydroxymethyl pyridine with N-methyl-1-phenyl-2,2'-iminodiethyl chloride to form 1-(3-hydroxymethylpyridyl-2)-4-methyl-2-phenyl piperazine, and adding sulfuric acid to the 1-(3-hydroxymethylpyridyl-2)-phenyl-4-methylpiperazine to form mirtazapine. The present invention also relates to new processes for recrystallization of mirtazapine from crude mirtazapine.

专利号:US-2003135043-A1
优先权日:1999-04-19
标题 :Novel synthesis and crystallization of piperazine ring-containing compounds

专利号:US-2004176591-A1
优先权日:1999-04-19
标 题:Novel synthesis and crystallization of peperazine ring-containing compounds